News Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:59:05 2026-03-11 pm EDT			5-day change	1st Jan Change
4.725 ^USD	+0.32%		-1.16%	-2.39%

Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT

All News

Mar. 04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
Mar. 04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT
Mar. 04	US Equity Markets End Higher After Strong Services, Jobs Data	MT
Mar. 04	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
Mar. 04	Wall Street mixed as oil retreat eases inflation fears
Mar. 04	Top Midday Stories: Bessent Says US to Fortify Gulf Oil Trade, 15% Tariff Rolling Out This Week; CrowdStrike Fiscal Q4 Adjusted Earnings, Revenue Increase	MT
Mar. 04	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
Mar. 04	Moderna to pay $950m to end litigation
Mar. 04	Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang	RE
Mar. 03	Moderna Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
Mar. 03	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute	RE
Mar. 03	Roivant announces Genevant Sciences' and Arbutus Biopharma's $2.25 billion global settlement with Moderna	RE
Mar. 03	Genevant Sciences and Arbutus Biopharma announce $2.25 billion global settlement with Moderna	RE
Mar. 03	Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna	GL
Feb. 18	Moderna Loses Two Defenses in Patent Infringement Case Against Arbutus Biopharma	MT
Jan. 16	Top Midday Decliners	MT
Jan. 16	Arbutus Biopharma Says European Patent Office Revokes Patent; Shares Fall	MT
Jan. 16	The Board of Appeal of the European Patent Office Revokes Arbutus Biopharma Corporation's European Patent EP 2279254	CI
Jan. 16	Arbutus Biopharma Corp - EPO revokes Arbutus Biopharma's European patent EP 2279254 - SEC filing	RE
Dec. 05	Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026	CI
Dec. 05	Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026	CI
Dec. 04	Trevi Therapeutics Names David Hastings CFO	MT
Nov. 14	Arbutus Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
Nov. 13	Arbutus Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Arbutus Biopharma Corporation Announces Additional Analysis of Imdusiran Clinical Data	CI